Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BKK Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
01
Overview
BKK Pharmaceuticals is an early-stage biotechnology company focused on the development of novel therapeutics for metabolic diseases, including obesity and type 2 diabetes. The company specializes in the discovery of small molecule agonists targeting key metabolic receptors such as GLP-1, GCG, and GIP. By leveraging expertise in medicinal chemistry and metabolic signaling, BKK Pharmaceuticals aims to create oral alternatives to existing injectable peptide therapies. Their current research is centered on optimizing lead compounds for improved potency and pharmacokinetic profiles in pre-clinical models.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on BKK Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BKK Pharmaceuticals.